Taiga Biotechnologies

BioTech/Drugs - Aurora, CO, US

Taiga Biotechnologies Employees
Vivienne Margolis

Director of Clinical Operations, Europe and Israel

Contact Vivienne Margolis

Thomas Payne

Director of Cellular Therapies

Contact Thomas Payne

Sarah Schmoker

Professional Research Assistant, Quality Assurance

Contact Sarah Schmoker

Robert Gulock

Chief Commercial Officer (CCO)

Contact Robert Gulock

Greg Bird

Director of Biologics

Contact Greg Bird

View All Taiga Biotechnologies Employees Contact All Taiga Biotechnologies Employees
Taiga Biotechnologies Details

Taiga Biotechnologies, Inc. is a clinical stage biotechnology company focused on harnessing the power of the immune system to fight solid tumors and infectious disease and on improving blood stem cell transplantation.What we do:• For healthy immune systems, our immunotherapy programs temporarily boost the immune system so that it functions better to fight both solid tumors and infectious disease. • For compromised immune systems, our regenerative medicine program generates a new, healthy immune system.1. Our lead Cell-Based Immunotherapy product candidate, TBX-3400, uses a patient's own immune cells to help fight against solid tumors and infectious disease. TBX-3400 is an autologous cell product made from peripheral blood mononuclear cells that are treated ex vivo with our fusion protein and then delivered intravenously back to the patient the following day. Our Cell-Based Immunotherapy technology has several advantages over current immunotherapy approaches. • We do not need to expand T-cells in the laboratory to generate enough T-cells for treatment.• We do not limit the response to the tumor based by engineering the specificity of the T-cell.• We do not require genetic modification of the T-cells to enable antitumor activity.2. Our Bone Marrow Engraftment Enhancer (BMEE) program is developing a first-line product, TBX-2400, to enhance the engraftment of hematopoietic stem and progenitor cells during an allogeneic hematopoietic stem cell transplant (HSCT). Our BMEE goal is to increase the chance of long-term survival of a HSCT recipient by:• increasing the probability of a successful engraftment;• increasing the rate of reconstitution of mature and functional lymphocytes; and• managing the complications associated with HSCT.

Taiga Biotechnologies logo, Taiga Biotechnologies contact details
Website: taigabiotech.com
Employees: 20 - 49
HQ: 720-859-3547
Location: Aurora, CO, US
Revenue: 20 - 50 Million
B2B Biotechnology Healthcare Pharmaceuticals BioTech/Drugs Commercial Physical Research
Taiga Biotechnologies Technologies
Email Providers

Outlook

Load Balancers

Varnish

CMS

Wix

Hosting

Google Cloud Hosting

Other

Mobile Friendly

View All Technologies Used At Taiga Biotechnologies

Contacting Taiga Biotechnologies: Connect with Executives and Employees

Get in Touch with Taiga Biotechnologies Executives and Employees

Connecting with Taiga Biotechnologies's Executives and Workforce

Accessing Contact Information for Taiga Biotechnologies Executives

Connecting with Taiga Biotechnologies: Reach Out to Their Team

Discover How to Contact Taiga Biotechnologies Executives and Staff

Looking to connect with Taiga Biotechnologies executives or employees?

Seeking to Get in Touch with Taiga Biotechnologies Executives or Staff?

Want to Reach Out to Taiga Biotechnologies Executives or Team Members?

In Search of Contact Details for Taiga Biotechnologies Professionals?

Connecting with Taiga Biotechnologies: Contacting Executives and Staff

Browse companies
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z